No Data
No Data
This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Jefferies Upgrades Crinetics(CRNX.US) to Buy Rating, Maintains Target Price $55
Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelman's Long-Term Stock Picks?
Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock With Biggest Upside Potential
While Crinetics Pharmaceuticals (NASDAQ:CRNX) Shareholders Have Made 75% in 3 Years, Increasing Losses Might Now Be Front of Mind as Stock Sheds 27% This Week
Oppenheimer Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $73